What are analysts'target prices for Rigel Pharmaceuticals'stock?
2 analysts have issued 12-month target prices for Rigel Pharmaceuticals' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Rigel Pharmaceuticals' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 292.6% from the stock's current price.
What is the upside for Rigel Pharmaceuticals'stock?
Their forecasts range from $8.00 to $11.00. On average, they expect Rigel Pharmaceuticals' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 292.6% from the stock's current price. View analysts' price targets for Rigel Pharmaceuticals or view top-rated stocks among Wall Street analysts.
Is Rigel Pharmaceuticals (Rige) stock a good dividend grower?
Rigel Pharmaceuticals does not have a long track record of dividend growth. In the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock. Only 5.63% of the stock of Rigel Pharmaceuticals is held by insiders. 80.62% of the stock of Rigel Pharmaceuticals is held by institutions.
Where can I buy shares of Rigl?
Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How were Reliv' International's earnings last quarter?
Reliv' International, Inc. (NASDAQ:RELV) issued its quarterly earnings data on Friday, May, 15th. The company reported $0.38 EPS for the quarter. T...
Who are Reliv' International's key executives?
Reliv' International's management team includes the following people: Mr. Robert L. Montgomery , Co-Founder & Chairman (Age 79, Pay $538.27k) Mr...
What is Ryan Montgomery's approval rating as Reliv' International's CEO?
1 employees have rated Reliv' International CEO Ryan Montgomery on Glassdoor.com . Ryan Montgomery has an approval rating of 100% among Reliv' Int...
Who are some of Reliv' International's key competitors?
Some companies that are related to Reliv' International include Pharmaxis (PXSLY) , Can-Fite BioPharma (CANF) , Can-Fite BioPharma (CANF) , Bio...
What other stocks do shareholders of Reliv' International own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Reliv' International investors own include VIVUS (VVUS) ,...
What is Reliv' International's stock symbol?
Reliv' International trades on the NASDAQ under the ticker symbol "RELV."
What is Reliv' International's stock price today?
One share of RELV stock can currently be purchased for approximately $3.97.
How much money does Reliv' International make?
Reliv' International (NASDAQ:RELV) has a market capitalization of $6.93 million and generates $35.06 million in revenue each year.
How many employees does Reliv' International have?
Reliv' International employs 91 workers across the globe.
RELX PLC (LON:REL) insider upped their holding earlier this year
Looking at RELX PLC's ( LON:REL ) insider transactions over the last year, we can see that insiders were net buyers...
Announcement of Non-Discretionary Share Buyback Programme
LONDON, February 10, 2022-- RELX PLC (the "Company") announces in compliance with the EU and UK Market Abuse Regulations that it will implement an irrevocable, non-discretionary programme to repurchase its ordinary shares up to the value of £150 million in total between 10 February 2022 and 20 April 2022 (the "Programme").
About Reliv' International
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer.
Headlines
Did You Manage To Avoid Reliv' International's (NASDAQ:RELV) Painful 60% Share Price Drop?
Reliv' International (NASDAQ:RELV) Frequently Asked Questions
Reliv' International, Inc. (NASDAQ:RELV) announced its quarterly earnings data on Friday, May, 15th. The company reported $0.38 EPS for the quarter. The business had revenue of $10.28 million for the quarter.
